Our grouphas recently identified RIG-I activation as a potentially promisingtarget for enhancing immunotherapy responses in triple-negative breastcancer (TNBC).28 Therefore, we evaluatedthe efficacy of systemically administered SLR-LNPs in an orthotopicEO771 breast cancer model. This evidence concerns the gene RIGI and breast carcinoma.